Premium
Topiramate therapy for paroxysmal kinesigenic choreoathetosis
Author(s) -
Huang YuanGui,
Chen YunChun,
Du Fang,
Li Rui,
Xu GeLin,
Jiang Wen,
Huang Jing
Publication year - 2005
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20283
Subject(s) - topiramate , choreoathetosis , medicine , dose , anticonvulsant , anesthesia , pediatrics , epilepsy , pharmacology , dystonia , psychiatry
We observed the clinical efficacy of topiramate for paroxysmal kinesigenic choreoathetosis (PKC). Topiramate was administered as a monotherapy with titrated dosages to 8 patients with PKC. Target daily dose of topiramate was 100 to 200 mg; the follow‐up period ranged from 8 months to 2 years. All of the patients became attack‐free, and side effects were mild. The results show that topiramate is effective as a monotherapy for treating patients with PKC. The response to topiramate indicates that the disease may be caused by an ion channel defect. © 2004 Movement Disorder Society
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom